Our project aims to treat infections by Pseudomonas aeruginosa by destroying its biofilm. It could be applied to various health problems in humans and animals.
As it would be applied to infection sites, it was very important to design a security system
that would prevent our engineered bacteria from colonizing the organism. This security system is
based on the fact that they can’t grow in absence of BHL. Therefore, the growth and store of our
PyoBusters have to be done in media containing BHL.
An element to take into consideration is that our bacteria would already be charged at the time of application, as our therapeutic molecules are constitutively produced and caused off-target therapeutic delivery.
To solve this problem we selected molecules that specifically affect Pseudomonas aeruginosa and its biofilm and with limited or no toxicity for eukaryotic cells and flora's prokaryotes. But we thought we can go even further in the security of our system by making the production of those therapeutic molecules BHL dependent, avoiding considerations about non-specific delivery.
For long term storage, we thought that we could lyophilize our PyoBuster. This
way, they can be easily stored for long periods and used as needed.
The easiest way to implement it would be in the context of otitis, as it could be locally applied as a solution on the infection site. It could also be used for burns and wounds as solutions or in pads that could be applied onto the wound. In the case of cystic fibrosis, we thought about nebulizing the bacterial solution. That way patients can inhale the treatment the same way they do for antibiotics.